Manual Therapy Improves Fibromyalgia Symptoms by Downregulating SIK1.
Bonastre-Férez, Javier, Giménez-Orenga, Karen, Falaguera-Vera, Francisco Javier et al. · International journal of molecular sciences · 2024 · DOI
Quick Summary
This study tested whether a specialized hands-on therapy treatment could help fibromyalgia patients and discovered why it might work. Researchers found that the treatment lowered levels of a specific gene called SIK1 in patients' blood cells, and this change was linked to improvements in pain, fatigue, and quality of life. Importantly, this gene change only happened in fibromyalgia patients who received the treatment—not in healthy people who got the same therapy.
Why It Matters
This research is relevant to ME/CFS because fibromyalgia and ME/CFS share overlapping symptoms including widespread pain, fatigue, and cognitive dysfunction, suggesting potential shared mechanisms. Identifying SIK1 as a disease-specific biomarker and therapeutic target offers a concrete molecular avenue for understanding and treating these debilitating conditions. The correlation between gene expression changes and clinical improvement provides a framework for developing and monitoring targeted treatments.
SIK1 downregulation correlated with improvements in hyperalgesia, allodynia, fatigue, and quality of life in treated FM patients.
The same manual therapy protocol did not produce SIK1 downregulation in non-FM control participants.
SIK1 downregulation appeared specific to the FM disease state rather than a general response to manual therapy.
RT-qPCR validation confirmed RNA-seq findings of SIK1 downregulation.
Inferred Conclusions
SIK1 may serve as a disease-specific biomarker for monitoring response to manual therapy in fibromyalgia.
SIK1 represents a potential therapeutic target for fibromyalgia treatment development.
Manual therapy's clinical benefits in FM may be mediated through FM-specific molecular pathways involving SIK1 regulation.
The FM-specific SIK1 response suggests distinct transcriptomic mechanisms in fibromyalgia compared to non-FM populations.
Remaining Questions
Does SIK1 downregulation directly cause symptom improvement, or is it a downstream marker of the therapeutic mechanism?
What This Study Does Not Prove
This study does not prove that lowering SIK1 directly causes symptom improvement—it only shows correlation. It does not establish whether SIK1 is a cause or consequence of fibromyalgia pathology. The findings are specific to fibromyalgia and cannot yet be generalized to ME/CFS without separate validation in ME/CFS populations.